Percutaneous chemical sensor based on fluorescence resonant energy transfer (FRET)

• US 20050267326A1
• Filed: 03/24/2005
• Published: 12/01/2005
• Est. Priority Date: 10/02/2001
• Status: Abandoned Application

• Current Assignee: The Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California (University of Southern California)
• Original Assignee: The Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California (University of Southern California)
• Inventors: Liao, Kuo-Chih (Vincent), Loeb, Gerald E., Hogen-Esch, Thieo
• Application Number:
  US11/088,460
• Publication Number:
  US 20050267326A1
• Time in Patent Office: Days
• US Class Current: 600/102
• CPC Class Codes: A61B 5/0071 by measuring fluorescence emission
• CPC Class Codes: A61B 5/0084 for introduction into the body, e.g. by catheters A61B5/1459 takes precedence
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61K 49/0041 Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal in vivo G01N
• CPC Class Codes: A61K 49/0043 Fluorescein, used in vivo
• CPC Class Codes: A61K 49/0052 Small organic molecules oligomers, polymers, dendrimers A61K49/0054
• CPC Class Codes: A61K 49/0054 Macromolecular compounds, i.e. oligomers, polymers, dendrimers
• CPC Class Codes: A61K 49/0067 quantum dots, fluorescent nanocrystals
• CPC Class Codes: G01N 2021/6432 Quenching
• CPC Class Codes: G01N 2021/772 Tip coated light guide
• CPC Class Codes: G01N 21/6428 Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" in vivo A61B5/00; immunoassay G01N33/53
• CPC Class Codes: G01N 21/645 Specially adapted constructive features of fluorimeters
• CPC Class Codes: G01N 21/7703 using reagent-clad optical fibres or optical waveguides using measurement of total internal reflection or attenuated total reflection G01N21/552; optical fibres or waveguides per se G02B

Abstract

A biosensing device for detecting biological analytes, and methods of use and manufacture, are disclosed. The device includes a biosensing element that can remain implanted for extended periods of time. The biosensing element is connected to an optical fiber terminating outside of the body. The optical fiber is also connected to an information analyzer. The information analyzer directs light through the optical fiber into the biosensing element. The light excites fluorophores, created by a chemical reaction between analytes and biosensing material within the biosensing element. Emitted fluorescent light is redirected through the optical fiber to the information analyzer. Detectors detect the deflected fluorescent emissions and, according to their determined wavelength, report the presence or quantity of specific analytes to the patient on an external display.

Claims

1. A device for detecting an analyte from within a patient'"'"'s body, comprising:

a) an optical fiber having;

a first end; and

a second end configured to intermittently connect and disconnect to an analyzer;

and

b) a biosensing material attached to the first end comprising;

a polymer matrix;

at least one receptor molecule attached to the polymer matrix and labeled with a first detector molecule; and

at least one competitive binding molecule attached to the polymer matrix and labeled with a second detector molecule, wherein the at least one receptor molecule is capable of interacting with the at least one attached competitive binding molecule and with at least one analyte from the patient'"'"'s body.

2. The device of claim 1, wherein the polymer matrix comprises polyethylene glycol.

3. The device of claim 1, wherein the at least one receptor molecule comprises a lectin.

4. The device of claim 3, wherein the at least one receptor molecule comprises concanavalin A.

5. The device of claim 1, wherein the at least one competitive binding analyte molecule comprises a polysaccharide.

6. The device of claim 5, wherein the polysaccharide comprises beta-cyclodextrin.

7. The device of claim 1, wherein the first and/or second detector molecule comprises a fluorophore.

8. The device of claim 7, wherein the first fluorophore comprises fluorescein isothiocyanate.

9. The device of claim 7, wherein the second fluorophore comprises tetramethylrhodamine isothiocyanate.

10. The device of claim 7, wherein the second fluorophore comprises a fluorescent semiconductor nanocrystal.

11. The device of claim 1, wherein the concentrations of the first and second detector molecules are low enough to minimize random proximity during FRET quenching, yet high enough to be detected by the analyzer.

12. The device of claim 7, wherein the size of the receptor and competitive binding molecule are not substantially larger than the Forster radius.

13. The device of claim 1, wherein the first end of the optical fiber further comprises a chemically altered adhesion region to which the biosensing material is attached.

14. The device of claim 1, wherein the first end of the optical fiber further comprises a mechanically altered adhesion region to which the biosensing material is attached.

15. A system for detecting an analyte from within a patient'"'"'s body, comprising:

a) an optical fiber comprising;

a first end; and

a second end configured to intermittently connect and disconnect to an analyzer;

b) a biosensing material attached to the first end comprising;

a polymer matrix;

at least one receptor molecule attached to the polymer matrix and labeled with a first detector molecule; and

at least one competitive binding molecule attached to the polymer matrix and labeled with a second detector molecule, wherein the at least one receptor molecule is capable of interacting with the at least one attached competitive binding molecule and with at least one analyte from the patient'"'"'s body;

and

c) an analyzer that is configured to rapidly and intermittently connect and disconnect to the second end of the optical fiber, and that is configured to emit light into the optical fiber, receive light from the biosensing material, and process information from the received light.

16. The system of claim 15, wherein the polymer matrix comprises polyethylene glycol.

17. The system of claim 15, wherein the at least one receptor molecule comprises a lectin.

18. The system of claim 17, wherein the at least one receptor molecule comprises concanavalin A.

19. The system of claim 15, wherein the at least one attached competitive binding molecule comprises a polysaccharide.

20. The system of claim 19, wherein the polysaccharide comprises beta-cyclodextrin.

21. The system of claim 15, wherein the first and/or second detector molecule comprises a fluorophore.

22. The system of claim 21, wherein the first fluorophore comprises fluorescein isothiocyanate.

23. The system of claim 21, wherein the second fluorophore comprises tetramethylrhodamine isothiocyanate.

24. The system of claim 21, wherein the second fluorophore comprises a fluorescent semiconductor nanocrystal.

25. The system of claim 15, wherein the concentrations of the first and second detector molecules are low enough to minimize random proximity during FRET quenching, yet high enough to be detected by the analyzer.

26. The system of claim 21, wherein the size of the receptor and analyte are not substantially larger than the Forster radius.

27. The system of claim 15, wherein the first end of the optical fiber further comprises a chemically altered adhesion region to which the biosensing material is attached.

28. The system of claim 15, wherein the first end of the optical fiber further comprises a mechanically altered adhesion region to which the biosensing material is attached.

29. The system of claim 15, wherein the analyzer is configured to automatically emit, receive, and analyze light upon insertion of the second end of the optical fiber.

30. The system of claim 15, wherein the analyzer further comprises a photodetector.

31. The system of claim 15, wherein the analyzer further comprises a tunable optical filter.

32. The system of claim 15, wherein the analyzer further comprises a user interface.

33. The system of claim 15, wherein the analyzer further comprises a substantially cone-shaped connecter by which the second end of the optical fiber connects to the analyzer.

34. A method of manufacturing an implantable biosensing device, comprising:

a) modifying the surface of a first end of an optical fiber to create an adhesion region;

b) submerging the first end of the optical fiber into a matrix precursor solution;

c) delivering ultraviolet light through a second end of the optical fiber; and

d) removing the first end of the optical fiber from the matrix precursor solution.

35. The method of claim 34, wherein the modifying step comprises immersing the first end of the optical fiber in an acidic solution to create an etched adhesion region.

36. The method of claim 35, wherein the modifying step further comprises cleaving off the end of the etched adhesion region.

37. The method of claim 34, further comprising repeating steps b) and d).

38. The method of claim 34, further comprising the step of applying ultraviolet light to the first end of the optical fiber.

39. The method of claim 34, wherein the modifying step comprises applying at least one chemical agent to the first end of the optical fiber to create an etched adhesion region.

40. The method of claim 38, wherein the at least one chemical agent comprises triethoxysilane.

41. The method of claim 34, wherein the modifying step comprises providing mechanical abrasion to the first end of the optical fiber to create an etched adhesion region.

42. The method of claim 34, wherein the matrix precursor solution comprises:

a) a polymer matrix;

b) at least one receptor molecule attached to the polymer matrix and labeled with a first detector molecule; and

c) at least one competitive binding molecule attached to the polymer matrix and labeled with a second detector molecule, wherein the at least one receptor molecule is capable of interacting with the at least one attached competitive binding molecules and with at least one analyte from the patient'"'"'s body.

43. A method of detecting an analyte from within a patient'"'"'s body, comprising:

a) implanting an optical fiber having an implanted and free end within the patient'"'"'s body such that the implanted end lies within the percutaneous region and the free end protrudes from the patient'"'"'s body;

b) allowing the implanted end of the optical fiber to remain in the percutaneous region of the body without removal for at least seven days;

c) allowing the free end of the optical fiber to remain unconnected to any device for a substantial portion of the at least seven days while the implanted end remains in the percutaenous region of the body;

d) connecting and disconnecting the free end to a measuring instrument; and

e) testing the analyte with the measuring instrument while it is connected to the free end;

wherein the optical fiber comprises;

a) a polymer matrix;

b) at least one receptor molecule attached to the polymer matrix and labeled with a first detector molecule; and

c) at least one competitive binding molecule attached to the polymer matrix and labeled with a second detector molecule, wherein the at least one receptor molecule is capable of interacting with the at least one attached competitive binding molecules and with at least one analyte from the patient'"'"'s body.

44. The method of claim 43, wherein the polymer matrix comprises polyethylene glycol.

45. The method of claim 43, wherein the at least one receptor molecule comprises a lectin.

46. The method of claim 45, wherein the at least one receptor molecule comprises concanavalin A.

47. The method of claim 43 wherein the at least one attached competitive binding molecule comprises a polysaccharide.

48. The method of claim 47, wherein the polysaccharide comprises beta-cyclodextrin.

49. The method of claim 43, wherein the first and/or second detector molecule comprises a fluorophore.

50. The method of claim 49, wherein the first fluorophore comprises fluorescein isothiocyanate.

51. The method of claim 49, wherein the second fluorophore comprises tetramethylrhodamine isothiocyanate.

52. The method of claim 49, wherein the second fluorophore comprises a fluorescent semiconductor nanocrystal.

53. The method of claim 43, wherein the concentrations of the first and second detector molecules are low enough to minimize random proximity during FRET quenching, yet high enough to be detected by the analyzer.

54. The method of claim 49, wherein the size of the receptor and analyte are not substantially larger than the Forster radius.

55. The method of claim 43, wherein the optical fiber further comprises a chemically altered adhesion region to which the biosensing material is attached.

56. The method of claim 43, wherein the optical fiber further comprises a mechanically altered adhesion region to which the biosensing material is attached.